You are here

  • Home
  • Archive
  • Volume 5, Issue 1
  • Correction: Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner

Article Text

Article menu

See original article:

Download PDFPDF

XML
Correction
Correction: Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner

https://doi.org/10.1136/bmjdrc-2017-000391corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Kitada M, Shin-ichi T, Konishi K et al. Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner. BMJ Open Diabetes Res Care 2017;5:e000391. doi:10.1136/bmjdrc-2017-000391.

    The funding statement has been amended to: This work was financially supported by a grant from the Kidney Foundation, Japan and SANWA KAGAKU KENKYUSHO CO, LTD to DK.

    Linked Articles